that the anaesthetics used during surgery may have longterm effects regarding chronic pain, as Salengros and colleagues 11 showed for remifentanil in patients who underwent a thoracotomy.
We performed a follow-up study of patients who participated in a clinical trial on pain levels in the early postoperative period in the intensive care unit (ICU) after cardiac surgery. The present study aimed to identify predictors for chronic thoracic pain 1 yr after cardiac surgery via sternotomy by analysing detailed patient and pre-, intra-, and postoperative characteristics.
Methods

Design and patients
A follow-up study was conducted in 120 patients who participated in a prospective, double-blind randomized clinical trial on procedural analgesia in the ICU after cardiac surgery (ClinicalTrials.gov identifier: NCT00558090). The inclusion criteria for this clinical trial were patient informed consent, admittance to the ICU after cardiac surgery via sternotomy, age between 18 and 85 yr, and body weight between 45 and 140 kg. Exclusion criteria were pregnancy or breast-feeding, an inability to communicate in either Dutch or English, coma or brain death, and a known morphine or acetaminophen (paracetamol) allergy. For the clinical trial, informed consent was given by 135 patients. Four patients were excluded directly after surgery because they were not admitted to the ICU but to the post-anaesthesia care unit (n¼3) or did not undergo a sternotomy (n¼1). Eleven patients died within 1 yr after surgery, resulting in 120 patients eligible for the follow-up study. The follow-up study was approved by the Ethics Committee (VCMO, Nieuwegein, The Netherlands) as an amendment to the clinical trial. Additional written informed consent was obtained from the patients.
Preoperative evaluations
Before operation, patient characteristics were collected and patients were questioned about their pain history, the use of analgesics, and preoperative pain score. For the latter, the Numeric Rating Scale (NRS) (range 0-10, with '0' representing 'no pain' and '10' representing 'the worst pain imaginable') was used.
Intraoperative anaesthesia and analgesia
For induction of anaesthesia, midazolam and propofol bolus injections were administered together with fentanyl. Patients were paralysed with pancuronium. Anaesthesia was primarily maintained with propofol, with an optional use of nitrous oxide. According to local practice, sevoflurane 0.25-1 minimum alveolar concentration was added for cardioprotection until the start of the extracorporeal circulation. For intraoperative analgesia, intermittent fentanyl doses were used, while a remifentanil continuous infusion was initiated directly after induction of anaesthesia at the discretion of the attending anaesthesiologist. Perioperative data were registered in the clinical trial registration form. In total, 18 anaesthesiologists and 10 surgeons were involved during surgery. The specific combination of a surgeon and an anaesthesiologist was unique for 43 patients and did not occur more than five times.
Postoperative pain measurement and analgesia in the ICU
According to the standard care in our ICU, a patient data management system (PDMS) obliged nurses to ask patients for their pain score three times a day (0:00, 8:00, and 16:00 h). 13 A pain titration protocol was used in all patients as part of standard care, consisting of intermittent acetaminophen (paracetamol) 4 g daily and a continuous i.v. infusion of morphine, which was started directly upon admittance to the ICU. According to the pain titration protocol, in the case of an NRS score of more than 3, an extra bolus of morphine, an increase in morphine continuous infusion, or both were applied. Pain scores were registered in the PDMS.
Follow-up study 1 yr after cardiac surgery
A questionnaire enquiring after the presence of chronic thoracic pain was sent to the patients 1 yr [13 months (SD 0.6)] after cardiac surgery. This previously used questionnaire 6 was based on the McGill Pain Questionnaire. 14 Chronic thoracic pain was defined as sternal and/or thoracic pain (NRS .0), which the patient identified as related to surgery, which was different from angina, and which was present in the 2 weeks preceding the interview. 6 
Data analysis
All statistical analyses were performed using IBM SPSS Statistics (version 19.0 for Windows; SPSS, Chicago, IL, USA). Descriptive statistics of patient characteristic and clinical variables were expressed as frequencies with percentages (%), median with inter-quartile range, or mean with standard deviation (SD) where appropriate. Categorical data were analysed by x 2 or Fisher's exact tests and continuous data by Student's t-tests or Mann -Whitney U-tests. In the case of significant differences in frequencies between patients with and without chronic pain in continuous or ordinal variables, receiver operating characteristic (ROC) curves were constructed to identify cut-off points with the most discriminative value. By using these cut-off points (dichotomization) and adding all other associated clinical variables (P,0.10), a backward stepwise logistic regression analysis was performed to identify variables with the most predictive value. Additionally, as a sensitivity analysis, the regression analysis was repeated without dichotomization. Imputation has been applied for 5 data entries (0.3% of all data entries).
A two-tailed P-value of ,0.05 was considered significant for all tests.
Results
Patients and data
Participant flow is summarized in a flow chart (Fig. 1) . Of the 120 questionnaires sent, 96 (80%) were returned. Two were returned blank and three questionnaires were accompanied by a note that these patients were unable to fill in the questionnaire. This resulted in 91 answered questionnaires. Univariate analysis of patient and pre-, intra-, and postoperative characteristics
One year after cardiac surgery, 20% of the patients (n¼18) reported chronic thoracic pain (NRS .0). Multivariate analysis of patient and pre-, intra-, and postoperative characteristics
In the multivariate logistic regression analysis, anaesthesia that included remifentanil, age younger than 69 yr, and a
Questionnaires sent n=120
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Excluded n=29 Inability to cooperate in follow-up (n=3 ) Questionnaire returned empty (n=2) Questionnaire not returned (n=24)
Excluded n=1
No information on doses of perioperative anaesthetics and analgesics BMI above 28 kg m 22 all appeared to be independent predictors for chronic thoracic pain with the corresponding ORs as shown in Table 3 . The goodness of fit of the final model was excellent (P-value by the Hosmer and Lemeshow test 0.94). Preoperative pain, chronic use of analgesics before surgery, and EuroSCORE were not statistically significant associated with chronic pain in the multivariate analysis. In analysis without dichotomization of continuous variables, remifentanil was confirmed as an independent predictor of chronic thoracic pain (adjusted OR 1.7; 95% CI 1.1-2.8).
Based on these findings, the association between remifentanil and chronic thoracic pain was examined in more detail. In total, 52 patients (58%) received remifentanil during cardiac surgery. Table 4 shows that there were no differences in patient characteristics or perioperative characteristics between patients who received remifentanil and patients who did not receive remifentanil. Table 5 shows the association between remifentanil dose administered during anaesthesia for cardiac surgery and OR for chronic thoracic pain 1 yr after surgery. Both with increasing total amounts of remifentanil (mg) and with increasing remifentanil dose corrected for kg LBM and duration of surgery, the OR for chronic thoracic pain increased with a 
Discussion
In addition to younger age and increased BMI, remifentanil during cardiac anaesthesia appears to be an independent predictor for chronic thoracic pain 1 yr after sternotomy. To the best of our knowledge, so far, chronic thoracic pain has not been associated with remifentanil in patients after cardiac surgery, although a relation between chronic postthoracotomy pain and remifentanil has been described. 11 Despite the fact that the current study was not designed to investigate the role of remifentanil in chronic pain after surgery, we found the relation between remifentanil and the OR for chronic thoracic pain to be dose-dependent. There were no other differences in patient and perioperative characteristics between patients who received remifentanil and those who did not. Furthermore, remifentanil was administrated in a substantial percentage of patients (58%) and was either started as a continuous infusion directly after the induction of anaesthesia, or not started at all. Therefore, the present study provided a unique possibility to compare patients with and without remifentanil during surgery, possibly leading to the identification of a risk factor for chronic pain that can actually be avoided. Chronic post-surgical pain related to remifentanil during anaesthesia has so far only been described by Salengros and colleagues 11 in patients after thoracotomy. Remifentanil high dose (0.14 -0.26 mg kg 21 min 21 ) during elective thoracotomy combined with postoperative epidural analgesia was not only associated with a larger area of allodynia around the wound in the first 72 postoperative hours, but also with a significant higher incidence of chronic pain compared with a three times lower dose of remifentanil and epidural analgesia during surgery. 17 -19 we were not able to evaluate pain scores in the first postoperative hour due to prolonged sedation after cardiac surgery. Therefore, we cannot report on the actual presence of acute opioid tolerance in our patients. Higher doses of remifentanil during cardiac surgery were, however, shown to be associated with hyperalgesia for the first 7 postoperative days compared with a 1.5 times lower dose of remifentanil when applied via target-controlled infusion. 19 Unfortunately, in the aforementioned study populations, the development of chronic pain was not evaluated. It can be anticipated that hyperalgesia is linked to peripheral and central pain sensitization and thereby correlates with the development of postoperative chronic pain. 20 This suggests that hyperalgesia due to remifentanil in the early postoperative period may explain the higher incidence of chronic pain. In addition to the finding of a dose-dependent association between remifentanil and development of chronic thoracic pain, the present study also confirmed an increased BMI (.28 kg m 22 ) and a younger age (,69 yr) as risk factors. 3 5 9 10 As surgery may be more difficult in the obese patient, with both a larger surface of tissue damaged and a longer retraction time, 9 this may explain the association between an increased BMI and chronic thoracic pain. For the observed association between younger age and the presence of chronic thoracic pain after surgery, Bruce and colleagues 9 have suggested that younger patients have a lower pain threshold and are less likely to accept and more likely to report pain. Another explanation is that younger patients are more active and more likely to be hampered by pain in their activities, whereas older patients may be more likely to accept their limitations. We consider some limitations of our study. First, the studied patients participated in a clinical trial on pain levels in the early postoperative period after cardiac surgery. This may have led to a selection bias because patients either may have had a specific reason not to participate or, on the contrary, may have been eager to participate in a study with the expectation of additional attention for pain and analgesia. On the other hand, the fact that the patients participated in this clinical trial, which resulted in a carefully prospectively monitored group of patients with detailed information on patient and perioperative characteristics, could be considered as a strength of the present study. Secondly, despite the high response rate of 75% of the questionnaires, selection bias cannot be excluded, as we have no information about the patients who did not respond. Thirdly, the continuous infusion of remifentanil during cardiac anaesthesia could be initiated after induction of anaesthesia at the discretion of the attending anaesthetist. Surgeons, surgical techniques, and anaesthetists were not randomized or standardized for the study, even though the large number of surgeons (n¼10) and anaesthesiologists (n¼18) without fixed combinations between the two could be considered a strength. More patients in the remifentanil group underwent a coronary artery bypass grafting (CABG) with the possible use of the left internal mammary artery, which has been associated with chronic pain. 21 Later studies could not confirm this association. 2 3 Patients with chronic pain did not, however, undergo a CABG more often than patients without chronic pain. These limitations make it impossible to draw more conclusions than the reported association between remifentanil and chronic thoracic pain after cardiac surgery. Unmeasured confounding cannot be ruled out, even though there were no significant differences in patient or other characteristics between the patients who received remifentanil and those who did not. As such, the results of this study, with higher amounts of remifentanil being significantly associated with higher ORs for chronic pain, warrant further blinded, randomized, and prospective studies as this may prevent the development of chronic thoracic pain or at least part of this serious condition. In further research, a follow-up at 3-6 months after cardiac surgery should be considered, thereby identifying chronic pain in an earlier period, which would increase the response rate.
In conclusion, chronic thoracic pain after sternotomy was associated with the use of remifentanil during cardiac surgery, younger patients, and an increased BMI. Higher doses of remifentanil were positively associated with significantly higher ORs for chronic pain. This is the second study that reports an association between remifentanil and chronic pain. Before this finding should be implemented in clinical practice in cardiac anaesthesia, further research through randomized controlled trials with and without remifentanil during cardiac surgery is called for, to investigate the influence of remifentanil on the development of chronic thoracic pain.
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